AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity

Chresta CM, Davies BR, Hickson I, Harding T, Cosulich S, Critchlow SE, Vincent JP, Ellston R, Jones D, Sini P, James D, …, Pass M · 2009 · Cancer research · Atlas ID CHR2009

What this study shows

AZD8055, an ATP-competitive mTOR kinase inhibitor, blocks both mTORC1 and mTORC2 (rapamycin-resistant outputs).

Abstract

ShowHide

The mammalian target of rapamycin (mTOR) kinase forms two multiprotein complexes, mTORC1 and mTORC2, which regulate cell growth, cell survival, and autophagy. Allosteric inhibitors of mTORC1, such as rapamycin, have been extensively used to study tumor cell growth, proliferation, and autophagy but have shown only limited clinical utility. Here, we describe AZD8055, a novel ATP-competitive inhibitor of mTOR kinase activity, with an IC50 of 0.8 nmol/L.

Read the full abstract on PubMed →

At a glance

Evidence type	M Molecular — cells, biochemistry, structure Marked M because it is molecular or in-vitro work (model: Cancer cells; xenograft) rather than a whole-organism health-outcome study. That is often exactly where causal biology gets established -- the code says which system the finding was shown in, and nothing about how good the work is.
Study type	5 - Mechanistic / In Vitro
Model system	Cancer cells; xenograft
Journal	Cancer research
Year	2009
Peer reviewed	Yes
Record last updated	2026-10-01
Source	DOI 10.1158/0008-5472.CAN-09-1751 · PMID 20028854

Extracted findings

These fields were extracted from the paper with AI assistance and have not been checked against the source. Read them as a pointer into the paper, not as curated claims; where they disagree with the curated summary above, the curated summary stands.

Intervention	AZD8055 (ATP-competitive mTOR inhibitor)
Target	mTORC1 & mTORC2
Model	Cancer cells; xenograft
Effect	AZD8055 is a potent, selective, orally bioavailable ATP-competitive mTOR inhibitor with antitumor activity

In the Atlas

Links in the pathway map

Supports ATP-competitive mTOR inhibitors inhibits mTORC1

Cite this paper

ShowHide

Chresta, C. M., Davies, B. R., Hickson, I., Harding, T., Cosulich, S., Critchlow, S. E., Vincent, J. P., Ellston, R., Jones, D., Sini, P., James, D., Howard, Z., Dudley, P., Hughes, G., Smith, L., Maguire, S., Hummersone, M., Malagu, K., Menear, K., Jenkins, R., Jacobsen, M., Smith, G. C., Guichard, S., & Pass, M. (2009). AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer research. https://doi.org/10.1158/0008-5472.CAN-09-1751

@article{CHR2009,
  author       = {Chresta, C. M. and Davies, B. R. and Hickson, I. and Harding, T. and Cosulich, S. and Critchlow, S. E. and Vincent, J. P. and Ellston, R. and Jones, D. and Sini, P. and James, D. and Howard, Z. and Dudley, P. and Hughes, G. and Smith, L. and Maguire, S. and Hummersone, M. and Malagu, K. and Menear, K. and Jenkins, R. and Jacobsen, M. and Smith, G. C. and Guichard, S. and Pass, M.},
  title        = {{AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity}},
  journal      = {Cancer research},
  year         = {2009},
  doi          = {10.1158/0008-5472.CAN-09-1751},
  note         = {PMID: 20028854},
}

Cite this Atlas record

The record is the Atlas's own work — the evidence label, the extracted findings and the links. It is cited as part of the dataset, not as the paper.

Barton, O. (2026). Oliver's mTOR Atlas (record CHR2009) [Data set]. https://mtor-atlas.org/study/CHR2009/ · Dataset DOI 10.5281/zenodo.22059963

@misc{atlas_CHR2009,
  author       = {Barton, Oliver},
  title        = {{Oliver's mTOR Atlas}, record CHR2009},
  howpublished = {Data set},
  year         = {2026},
  url          = {https://mtor-atlas.org/study/CHR2009/},
  doi          = {10.5281/zenodo.22059963}
}

Was this page useful?